

Editorial

Bench and Bedside

Christian Schmidt^{1,2}

Address: ¹Editor-in-Chief, Molecular Cancer, BioMed Central Ltd, Middlesex House, 34-42 Cleveland Street, London W1T 4LB, UK and ²The University of Texas M. D. Anderson Cancer Center, Department of Surgical Oncology and Molecular Oncology, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA

E-mail: christian.schmidt@molecular-cancer.org

Published: 9 July 2002

Molecular Cancer 2002, 1:1

Received: 29 June 2002

Accepted: 9 July 2002

This article is available from: <http://www.molecular-cancer.com/content/1/1/1>

© 2002 Schmidt; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any purpose, provided this notice is preserved along with the article's original URL.

These are exciting times in cancer research; significant advances in cancer biology are now being effectively translated into the clinic and technological advances such as gene expression profiling are allowing the characterisation of cancerous lesions at the molecular level and the identification of markers of prognostic value. In this context, I am proud to introduce *Molecular Cancer* [<http://www.molecular-cancer.com>], a new forum for cutting-edge findings in cancer research.

This open access, online journal is interested in a wide range of manuscripts presenting original research and commentary. For original research, the common thread is that the work should reveal novel concepts of broad importance to the scientific community. *Molecular Cancer* publishes Reviews, Original research, Case reports, Short communications and Hypotheses.

Reviews are invited and should be of public interest. The common thread of Original research and Case reports is that they reveal novel concepts of wide importance and interest to the scientific community, with conclusions that deliver a substantial advance in understanding of an important problem. Short communications are preliminary results of exceptional interest that are particularly topical and relevant, and for which fast publication is essential. Hypotheses are ideas or critics of ideas with discussion that will deliver a substantial advance in the understanding of an important problem.

I obtained my Ph.D. from the University of Rostock, Germany, for my work on mechanotransduction [1]. From my collaborations with scientists at biotech companies and with clinicians, I came to recognise the need for a dynamic forum that fosters the exchange of ideas across the entire cancer community. We now have an opportunity to make *Molecular Cancer* just such a journal, and this is an exciting challenge. Assisting me in this new venture are Guido M. Scabas, as Deputy Editor, and R. Scott Heller as Associate Editor. Guido has a background in surgical oncology and growth factor signalling. Scott's research focuses on Wnt signalling and pancreas development.

For *Molecular Cancer* to become an exciting forum for cancer research, we need you to contribute your most innovative and significant work in the cancer field. In exchange, *Molecular Cancer* will strive to provide a fast, fair, and constructive review process; the highest quality production values; and a dedicated team of professional scientific editors, who are willing to discuss your research, respond to your presubmission inquiries, and ensure that all manuscripts are reviewed on the basis of scientific merit and held to the highest standards of excellence and editorial consistency.

I would like to take this opportunity to acknowledge our Editorial Board [<http://www.molecular-cancer.com/editorial-board/>] for their commitment to the journal and to express my most sincere gratitude to the entire staff of BioMed Central [<http://www.biomedcentral.com/>] for

their valuable advice and support in launching this journal.

I invite you to work together with us to develop this new forum for cancer research, and I look forward to meeting you at conferences throughout the year.

References

1. Schmidt C, Pommerenke H, Dürr F, Nebe B, Rychly J: **Mechanical stressing of integrin receptors induces enhanced tyrosine phosphorylation of cytoskeletally anchored proteins.** *J Biol Chem* 1998, **273**:5081-5085

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMedcentral will be the most significant development for disseminating the results of biomedical research in our lifetime."

Paul Nurse, Director-General, Imperial Cancer Research Fund

Publish with **BMC** and your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours - you keep the copyright

Submit your manuscript here:

<http://www.biomedcentral.com/manuscript/>



BioMedcentral.com

editorial@biomedcentral.com